Efficacy, Quality of Life Improvement, and Longevity of Risankizumab in Individuals with Moderate-to-Severe Psoriasis: Insights from the PRIMMA Study's Real-World Data

1

Risankizumab significantly improved quality of life in 58% of patients with moderate-to-severe psoriasis after 52 weeks of treatment.
2

After treatment, 81% of patients reported low pruritus levels, indicating a substantial reduction in itch severity.
3

The study demonstrated that risankizumab led to improvements in sleep quality, work productivity, and activity impairment.
4

Digital monitoring of nocturnal scratching showed significant reductions in scratch duration among patients receiving risankizumab.
5

Integrating digital scratch measures with patient-reported outcomes may enhance management strategies for psoriasis.

Dermatology And Therapy (Springer)

by Igor Snast, Yuliya Valdman-Grinshpoun, Naji Bathish, Hagit Matz, Yuri Shclar, Sari Murad, Tali Czarnowicki, Eran Shavit, Liuqing Yang, Sandra Goss, Inbal Piller Maor, Assaf Halperin, Shiran Naftalberg Blonder, Raanan Cohen, Alex Bleterman, Moran Barak, Lev Pavlovsky
March 31, 2026

1